To what extent do bioinformatic tools such as CB Dock 2 and Chimera help in the analysis of phytochemicals (Calotropone, Quercetin, Thymoquinone) compared to allopathic drugs (Gemcitabine, Olaparib, Fluorouracil) against target receptors of pancreatic cancer (human glutamate oxaloacetate transaminase 1 (GOT1), threonine-protein kinase BUB1, and Peroxisome proliferator-activated receptor gamma)?
